![Kate Gillian Storey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kate Gillian Storey
Direttore/Membro del Consiglio presso The Company of Biologists Ltd.
Posizioni attive di Kate Gillian Storey
Società | Posizione | Inizio | Fine |
---|---|---|---|
The Company of Biologists Ltd.
![]() The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Kate Gillian Storey
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
The Company of Biologists Ltd.
![]() The Company of Biologists Ltd. Miscellaneous Commercial ServicesCommercial Services The Company of Biologists Ltd. is a not-for-profit publishing organization that supports and inspires the biological community. The non-profit company is based in Histon, UK. The British company is run by distinguished practicing scientists and exist to profit science, not shareholders. The company publishes leading peer-reviewed journals such as Development, Journal of Cell Science, and Journal of Experimental Biology. The company offers a range of resources to early-career researchers and have chosen the 'transformative' route towards Open Access. The company promotes the use of Caenorhabditis elegans to investigate ten of the 14 cancer hallmarks that define the mechanisms of cancer. | Commercial Services |
- Borsa valori
- Insiders
- Kate Gillian Storey
- Esperienza